|
NCT04371406
|
Efficacy of Azithromycin-associated Hydroxychloroquine Therapy Given in General Practice in Early-stage Disease in COVID-19 Patients |
Withdrawn |
Phase 3 |
Apr/01/2020 |
Sep/01/2020 |
- Alternative id - APHP200447|2020-001702-35
- Interventions - Drug: Hydroxychloroquine and Azithromycin|Dietary Supplement: Azinc
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Rate of patients with occurrence of an unfavorable outcome between randomization and day 14|Primary outcome of ancillary virological study : evolution of viral load between day 0 and day 14|The all-cause mortality rate at day 14|The all-cause mortality rate at day 28|Rate of patients with occurrence of an unfavorable outcome between randomization and day 28|The rate of use of mechanical ventilation at day 14|The rate of use of mechanical ventilation at day 28|The Intensive Care Unit admission rate at day 14|The Intensive Care Unit admission rate at day 28|Number of days of hospitalization for any cause between day 0 and day 14|Number of days of hospitalization for any cause between day 0 and day 28|The time to resolution of all COVID symptoms at day 14|The time to resolution of all COVID symptoms atday 28|The rate of use of oxygen therapy at day 14|The rate of use of oxygen therapy at day 28|The rate of use of secondary antibiotic therapy (after day 2) at day 14|The rate of use of secondary antibiotic therapy (after day 2) at day 28|Clinical status at day 14|Clinical status at day 28|number of serious adverse events at day 14|number serious adverse events at day 28|number of adverse events at day 14|number of adverse events at day 28|The rate of patients with treatment withdrawal|Ancillary virological study : rate of patients with negative viral load at day 8|Ancillary virological study : rate of patients with negative viral load at day 14
|
|
NCT04329832
|
Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 |
Active, not recruiting |
Phase 2 |
Mar/30/2020 |
Dec/31/2021 |
- Alternative id - 1051355
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 85
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - COVID Ordinal Outcomes Scale at 14 days|Hospital-free days at 28 days (number of days patient not in hospital)|Ventilator-free days at 28 days (number of days patient not on a ventilator)|ICU-free days at 28 days (number of days patient not in an ICU)|Time to a 1-point decrease in the WHO ordinal recovery score
|
|
NCT04369365
|
A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic |
Recruiting |
Phase 2 |
Apr/27/2020 |
Dec/27/2020 |
- Alternative id - OnCoVID-19 Trial
- Interventions - Drug: Azithromycin 500 milligram (mg) oral Tablet|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - AKH Vienna, Department for Internal Medicine I, Oncology, Vienna, Austria
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Prevention
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Cumulative number of severe acute respiratory syndrome corona virus 2 (SARS-COV-2) infections|Number of severe COVID-19 cases|Severity of COVID-19 cases|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of viral and bacterial infections|Number of participants with azithromycin-resistant bacterial strains in nasal swabs test
|
|
NCT04354597
|
Hydroxychloroquine and Azithromycin as Prophylaxis for Healthcare Workers Dealing With COVID19 Patients |
Withdrawn |
Not Applicable |
May/01/2020 |
Oct/15/2020 |
- Alternative id - 20 KHCC 67
- Interventions - Drug: HCQ & AZ
- Study type - Interventional
- Study results - No Results Available
- Locations - King Hussein Cancer Center, Amman, Jordan
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
- Enrollment - 0
- Age - 25 Years to 70 Years (Adult, Older Adult)
- Outcome measures - Effect of HCQ and AZ in preventing infection with COVID-19 among healthcare workers working with COVID-19 patients|Safety of HCQ and AZ|Oxygen requirement|ICU admission|Mortality rate
|
|
NCT04339426
|
Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection |
Terminated |
Phase 2 |
Apr/20/2020 |
Feb/11/2022 |
- Alternative id - HRI-COVID-19-Anti-Malarial-001
- Interventions - Drug: Atovaquone/Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - HonorHealth, Scottsdale, Arizona, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 3
- Age - 18 Years to 95 Years (Adult, Older Adult)
- Outcome measures - Virology Cure Rate|Incidence of GI adverse events|Cardiac Toxicity
|
|
NCT04344444
|
Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease |
Terminated |
Phase 3 |
Apr/13/2020 |
Jan/05/2022 |
- Alternative id - COVID 2020-001
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - University Medical Center New Orleans, New Orleans, Louisiana, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 22
- Age - 18 Years to 100 Years (Adult, Older Adult)
- Outcome measures - Most severe outcome
|
|
NCT04622891
|
Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection |
Completed |
Not Applicable |
Apr/01/2020 |
Jul/30/2020 |
- Alternative id - SVU-MED-CHT019-420860
- Interventions - Drug: Clarithromycin 500mg|Drug: Azithromycin|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - south-Vally University faculty of medicine, Qena, Egypt
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 300
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - time to fever control|PCR conversion
|
|
NCT04363203
|
VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL) |
Suspended |
Phase 3 |
Apr/30/2020 |
Aug/01/2021 |
- Alternative id - 20-30517
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Placebo oral tablet
- Study type - Interventional
- Study results - No Results Available
- Locations - San Francisco VA, San Francisco, California, United States
- Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 300
- Age - 216 Months and older (Adult, Older Adult)
- Outcome measures - Days to resolution of cough, fever and shortness of breath|Days to resolution of all COVID-19 symptoms|All cause hospitalization|All cause mortality|COVID-19 specific mortality|COVID-19 specific hospitalization
|
|
NCT04365231
|
Hydroxychloroquine Azithromycin COVID-19 Pregnancy Trial |
Withdrawn |
Phase 3 |
Apr/01/2020 |
Apr/01/2021 |
- Alternative id - HASCOPT2020
- Interventions - Drug: Hydroxychloroquine and azithromycin treatment|Other: conventional management of patients
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Percentage of patients with a negative RT-PCR test result to COVID-19|Maternal outcomes: Percentage of severe forms of the disease|Newborn outcomes: Rate of newborns hospitalized in intensive care or transferred to resuscitation unit
|
|
NCT04335552
|
Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection |
Terminated |
Phase 2 |
Apr/17/2020 |
Jun/26/2020 |
- Alternative id - PRO00105339
- Interventions - Other: Standard of care|Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - Has Results
- Locations - Duke Regional Hospital, Durham, North Carolina, United States|Duke University Hospital, Durham, North Carolina, United States|Durham VA Medical Center, Durham, North Carolina, United States|Duke Raleigh Hospital, Raleigh, North Carolina, United States
- Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 11
- Age - 12 Years and older (Child, Adult, Older Adult)
- Outcome measures - World Health Organization (WHO) Ordinal Scale Measured at 14 Days After Enrollment|Number of Participants Who Died During the Index Hospitalization|Number of Days on Mechanical Ventilation|Number of Patients Not Receiving Mechanical Ventilation at Baseline Who Progress to Requiring Mechanical Ventilation During the Index Hospitalization|WHO Ordinal Scale Measured at 28 Days After Enrollment|Hospital Length of Stay in Days for the Index Hospitalization|Number of Participants With All-cause Study Medication Discontinuation|Number of Participants With Severe Adverse Events
|
|
NCT04501965
|
Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients |
Enrolling by invitation |
Phase 2 |
Jun/01/2020 |
Sep/30/2020 |
- Alternative id - IRDPMAG
- Interventions - Combination Product: Hydroxychloroquine/Azithromycine|Combination Product: Quinquina-Stevia/Azythromycin|Combination Product: 4Plants/Azythromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Support Centers of Donka, Kenien and Gbessia, Conakry, Guinea
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 231
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Virologic clearance of throat swabs or lower respiratory tract secretions|COVID-19 symptoms development|Adverse effects|Worsened condition
|
|
NCT04715295
|
Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19 |
Recruiting |
Phase 4 |
Oct/05/2020 |
Sep/05/2021 |
- Alternative id - CNO0032020
- Interventions - Drug: Doxycycline Tablets|Drug: Rivaroxaban 15Mg Tab|Combination Product: Hydroxychloroquine and Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Yaounde Central Hospital, Yaounde, Centre, Cameroon
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Clinical|Virological|Symptom remission|Hospitalisation|Mortality|Biological variables
|
|
NCT04699097
|
The Effect of Azithromycin Use on Conduction System of Heart in COVID-19 Positive Children |
Completed |
|
Jul/01/2020 |
Nov/01/2020 |
- Alternative id - 139
- Interventions - Drug: Azithromycin
- Study type - Observational
- Study results - No Results Available
- Locations - Süleyman Sunkak, Kayseri, In The USA Or Canada, Please Select..., Turkey
- Study designs - Observational Model: Case-Only|Time Perspective: Prospective
- Enrollment - 105
- Age - 1 Year to 18 Years (Child, Adult)
- Outcome measures - Effect of azitromycin on ventricle repolarization
|
|
NCT04329572
|
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Hospitalized Patients With Moderate to Severe COVID-19 |
Suspended |
Early Phase 1 |
Apr/23/2020 |
Jun/30/2020 |
- Alternative id - HIAPRE0320OR
- Interventions - Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets
- Study type - Interventional
- Study results - No Results Available
- Locations - Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 400
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Evolution of acute respiratory syndrome, oxygen saturation hemodynamic stability|Viral load|Change in Clinical Condition|Evolution of Acute Respiratory Syndrome|Hospital discharge|Rate of mortality within 28-days
|
|
NCT04365582
|
OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor Outcome |
Withdrawn |
Phase 3 |
May/07/2020 |
Apr/19/2021 |
- Alternative id - OUTCOV
- Interventions - Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Lopinavir 200Mg/Ritonavir 50Mg Tab
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 50 Years and older (Adult, Older Adult)
- Outcome measures - Hospital admission|Effect of treatment on Death at D20|Effect of treatment on Death at D60|Effect of treatment on Death due to COVID at D20|Effect of treatment on Death due to COVID at D60|Effect of treatment on need for ICU stay at D20|Effect of treatment on need for ICU stay at D60|Effect of treatment on duration of ICU stay at D20|Effect of treatment on duration of ICU stay at D60|Effect of treatment on need of mechanical ventilation at D20|Effect of treatment on need of mechanical ventilation at D60|Effect of treatment on duration of mechanical ventilation at D20|Effect of treatment on duration of mechanical ventilation at D60|Effect of treatment on time to hospitalization at D20|Effect of treatment on time to hospitalization at D60|Effect of treatment on Duration of Hospital stay et D20|Effect of treatment on Duration of Hospital stay et D60|Effect of treatment on Duration of symptoms at D20|Effect of treatment on Duration of symptoms at D60|Incidence of Treatment-Emergent Adverse Events
|
|
NCT04341870
|
Study of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients: Sarilumab, Azithromycin, Hydroxychloroquine Trial - CORIMUNO-19 - VIRO |
Suspended |
Phase 2|Phase 3 |
Apr/11/2020 |
Aug/01/2020 |
- Alternative id - APHP200375-3
- Interventions - Drug: Sarilumab|Drug: Azithromycin|Drug: Hydroxychloroquine
- Study type - Interventional
- Study results - No Results Available
- Locations - AP-HP Hôpital Avicenne, Bobigny, France|AP-HP Hôpital Ambroise Paré, Boulogne-Billancourt, France|AP-HP Hôpital Beaujon, Clichy, France|AP-HP Hôpital Pitié Salpétrière, Paris, France|AP-HP Hôpital Saint Antoine, Paris, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 27
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - Need for ventilation (including invasive and non invasive ventilation), intensive care or death|Early improvement: OMS progression scale <= 5|OMS progression scale|Survival|ICU-free days alive|Ventilation-free days alive|Hospital-free days alive|Oxygen therapy-free days alive|Time to negative viral excretion|Immunophenotyping and multiplex cytokines
|
|
NCT04349410
|
The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol |
Completed |
Phase 2|Phase 3 |
Apr/11/2020 |
Sep/14/2020 |
- Alternative id - FMTVDM2020
- Interventions - Drug: Hydroxychloroquine, Azithromycin|Drug: Hydroxychloroquine, Doxycycline|Drug: Hydroxychloroquine, Clindamycin|Drug: Hydroxychloroquine, Clindamycin, Primaquine - low dose.|Drug: Hydroxychloroquine, Clindamycin, Primaquine - high dose.|Drug: Remdesivir|Drug: Tocilizumab|Drug: Methylprednisolone|Drug: Interferon-Alpha2B|Drug: Losartan|Drug: Convalescent Serum
- Study type - Interventional
- Study results - No Results Available
- Locations - FHHI-OI-Camelot; QME, Los Angeles, California, United States
- Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment
- Enrollment - 1800
- Age - Child, Adult, Older Adult
- Outcome measures - Improvement in FMTVDM Measurement with nuclear imaging.|Ventilator status|Survival status
|
|
NCT04368351
|
Bacteriotherapy in the Treatment of COVID-19 |
Active, not recruiting |
|
Mar/01/2020 |
Jul/31/2020 |
- Alternative id - DPHID-UniRoma05
- Interventions - Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine
- Study type - Observational
- Study results - No Results Available
- Locations - Department of Public Heath and Infectious Diseases. University of Rome "Sapienza" (Italy), Rome, Italy
- Study designs - Observational Model: Case-Control|Time Perspective: Retrospective
- Enrollment - 70
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - delta of time of disappearance of acute diarrhea|Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital
|
|
NCT04457609
|
Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients |
Recruiting |
Phase 1 |
Jul/01/2020 |
Sep/01/2020 |
- Alternative id - ISMMSCCOVID19
- Interventions - Drug: Oseltamivir|Drug: Azithromycin|Biological: Umbilical Cord Mesenchymal Stem Cells
- Study type - Interventional
- Study results - No Results Available
- Locations - Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia|Persahabatan General Hospital, Jakarta, DKI Jakarta, Indonesia|Sulianti Saroso Center for Infectious Disease, Jakarta, DKI Jakarta, Indonesia|Universitas Indonesia Hospital, Depok, West Java, Indonesia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 40
- Age - 18 Years to 95 Years (Adult, Older Adult)
- Outcome measures - Clinical improvement: Presence of dyspnea|Clinical improvement: presence of sputum|Clinical improvement: fever|Clinical improvement: ventilation status|Clinical improvement: blood pressure|Clinical improvement: heart rate|Clinical improvement: respiratory rate|Clinical improvement: oxygen saturation|General laboratory outcome from leukocyte level|General laboratory outcome from lymphocytes level|General laboratory outcome from blood pH|General laboratory outcome from blood level of CO2|General laboratory outcome from blood base excess level|General laboratory outcome from blood oxygen partial pressure|General laboratory outcome from blood level of HCO3|General laboratory outcome from blood level of O2 saturation|General laboratory outcome from level of CRP|General laboratory outcome from level of SGOT/SGPT (AST/ALT)|General laboratory outcome from the level of ureum/creatinine level|General laboratory outcome from the level of eGFR|General laboratory outcome from the level of sodium|General laboratory outcome from the level of potassium|General laboratory outcome from the level of chloride|Changes in procalcitonin level|General laboratory outcome from albumin level|General laboratory outcome from total bilirubin level|Changes in D-Dimer level|Changes in fibrinogen level|Cardiac changes from troponin level|Cardiac changes from NT proBNP level|Changes in Leukemia Inhibiting Factor|Changes in level of IL-6|Changes in level of IL-10|Changes in level of vascular endothelial growth factor (VEGF)|Changes in level of ferritin|Changes in level of CXCR3|Changes in level of CD4|Changes in level of CD8|Changes in level of CD56|Radiologic Improvement from Chest X-Ray/CT Scan
|
|
NCT04399746
|
Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19 |
Completed |
Not Applicable |
Mar/15/2020 |
Jun/10/2020 |
- Alternative id - IvAzCol
- Interventions - Drug: Ivermectin|Drug: Azithromycin|Drug: Cholecalciferol
- Study type - Interventional
- Study results - No Results Available
- Locations - Outpatient treatment, Mexico City, Mexico
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 30
- Age - 18 Years to 90 Years (Adult, Older Adult)
- Outcome measures - Viral clearance|Symptoms duration|SpO2|SpO2/FiO2
|
|
NCT04954040
|
Prevention and Treatment With Hydroxychloroquine + Azithromycin of Acute Respiratory Syndrome Induced by COVID-19 |
Recruiting |
Phase 2 |
Feb/10/2021 |
Dec/01/2021 |
- Alternative id - AMBUCOV
- Interventions - Drug: Hydroxychloroquine Pill + Azithromycin Pill|Drug: SOC
- Study type - Interventional
- Study results - No Results Available
- Locations - Centro de Salud Priego de Córdoba, Priego de Córdoba, Córdoba, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 132
- Age - 18 Years to 90 Years (Adult, Older Adult)
- Outcome measures - Hospitalization|ICU admission|Death|Clinical Evolution
|
|
NCT04341207
|
Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients |
Recruiting |
Phase 2 |
Apr/03/2020 |
Apr/01/2022 |
- Alternative id - 2020-001250-21|2020/3078
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Gustave Roussy, Villejuif, Val De Marne, France
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 1000
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Prevalence and the 3-months incidence of SARS-CoV-2 in cancer patients|Covid-19 disease-specific mortality rate in cancer patients treated by hydroxychloroquine and azithromycin
|
|
NCT04321278
|
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II) |
Completed |
Phase 3 |
Mar/28/2020 |
Jun/14/2020 |
- Alternative id - 30155020.5.1001.0071
- Interventions - Drug: Hydroxychloroquine + azithromycin|Drug: Hydroxychloroquine
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital de Urgência e Emergência de Rio Branco, Rio Branco, AC, Brazil|Hospital e Clínica São Roque, Ipiaú, BA, Brazil|Hospital da Cidade, Salvador, BA, Brazil|Hospital Maternidade São Vicente de Paulo, Barbalha, CE, Brazil|Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, CE, Brazil|Hospital Unimed Cariri, Juazeiro Do Norte, CE, Brazil|Hospital Brasilia, Brasilia, DF, Brazil|Hospital Estadual Jayme dos Santos Neves, Serra, ES, Brazil|Hospital Evangélico de Vila Velha, Vila Velha, ES, Brazil|Secretaria de Estado de Saúde de Goias, Goiânia, GO, Brazil|Santa Casa de Misericórdia de Belo Horizonte Santa Casa de BH, Belo Horizonte, MG, Brazil|Hospital Santa Paula, Passos, MG, Brazil|Santa Casa da Misericordia - UTI (São João Del Rey), São João Del Rei, MG, Brazil|Hospital Maternidade E Pronto Socorro Santa Lucia Ltda, Poços De Caldas, Minas Gerais, Brazil|Universidade Estadual de Londrina, Londrina, Paraná, Brazil|Hospital Adventista de Belém, Belém, Pará, Brazil|Hospital Adventista de Belem, Belem, PA, Brazil|Procape - Pronto S.Cardiologico de Pe.Prof.Luiz Tavares-, Recife, PE, Brazil|Liga Paranaense de Combate ao Câncer, Curitiba, PR, Brazil|Hospital Giselda Trigueiro, Natal, Rio Grande Do Norte, Brazil|Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil|Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre, Rio Grande Do Sul, Brazil|Hospital Naval Marcílio Dias, Rio de Janeiro, RJ, Brazil|Hospital São Lucas, Rio De Janeiro, RJ, Brazil|Hospital Maternidade PROMATER, Natal, RN, Brazil|Associação Dr. Bartholomeu Tacchini, Bento Gonçalves, RS, Brazil|Hospital Geral de Caxias do Sul, Caxias Do Sul, RS, Brazil|Hospital Bruno Born, Lajeado, RS, Brazil|Hospital São Vicente de Paulo, Passo Fundo, RS, Brazil|Maestri E Kormann Consultoria Medico-Cientifica, Blumenau, Santa Catarina, Brazil|Sociedade Literaria e Caritativa Santo Agostinho, Criciúma, Santa Catarina, Brazil|Hospital Nereu Ramos, Florianópolis, SC, Brazil|Hospital Universitário Polydoro Ernani de São Thiago/HU - UFSC, Florianópolis, SC, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital Dona Helena, Joinville, SC, Brazil|Hospital Municipal Sao Jose, Joinville, SC, Brazil|Hospital Regional Hans Dieter Schmidt, Joinville, SC, Brazil|Faculdade de Medicina de Botucatu, Botucatu, SP, Brazil|nstituto de Pesquisa Clínica de Campinas, Campinas, SP, Brazil|Fundação do ABC (Hospital Estadual Mário Covas), Santo André, SP, Brazil|AC Camargo Cancer Center - Fundação Antonio Prudente, São Paulo, SP, Brazil|Casa de Saude Santa Marcelina, São Paulo, SP, Brazil|Hospital Alemão Oswaldo Cruz, São Paulo, SP, Brazil|Hospital Moriah, São Paulo, SP, Brazil|Hospital Nove de Julho, São Paulo, SP, Brazil|Hospital Santa Paula, São Paulo, SP, Brazil|Hospital São Camilo Pompeia, São Paulo, SP, Brazil|Fundação Pio XII, Barretos, São Paulo, Brazil|Santa Casa de Misericordia de Votuporanga, Votuporanga, São Paulo, Brazil|Hospital Israelita Albert Einstein, São Paulo, Brazil|A Beneficência Portuguesa de São Paulo - BP, São Paulo, Brazil|Associacao Beneficente Siria, São Paulo, Brazil|Hospital Vila Santa Catarina, São Paulo, Brazil|Real e Benemérita Associação Portuguesa de Beneficência/SP - 1, São Paulo, Brazil|Secretaria de Saúde do Estado de São Paulo, São Paulo, Brazil|Serv Social da Industria do papel, papelão e cortiça do estado de SP, São Paulo, Brazil|Sociedade Beneficente de Senhoras Hospital Sírio-Libanês, São Paulo, Brazil|Universidade Federal de São Paulo, São Paulo, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 440
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Evaluation of the clinical status|All-cause mortality|Number of days free from mechanical ventilation|Duration of mechanical ventilation|Duration of hospitalization|Other secondary infections|Time from treatment start to death|Medium and long-term outcomes of SARS-CoV2 infection on morbimortality, daily life activities, mental health, and quality of life|Assess whether the tested therapies may be affected by leucocyte phenotype
|
|
NCT04380818
|
Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19 |
Recruiting |
Not Applicable |
Jun/05/2020 |
Nov/01/2021 |
- Alternative id - IPACOVID
- Interventions - Radiation: Low-dose radiotherapy|Drug: Hydroxychloroquine Sulfate|Drug: Ritonavir/lopinavir|Drug: Tocilizumab Injection [Actemra]|Drug: Azithromycin|Drug: Corticosteroid|Drug: Low molecular weight heparin|Device: Oxygen supply
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Sant Joan de Reus, Reus, Tarragona, Spain|Hospital Del Mar, Barcelona, Spain|Hospital Universitario Madrid Sanchinarro, Madrid, Spain
- Study designs - Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
- Enrollment - 106
- Age - 18 Years to 99 Years (Adult, Older Adult)
- Outcome measures - Efficacy of low-dose pulmonary irradiation assessed by change in PAFI O2 by 20%|Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change of the radiological image|Overall mortality|Measure of pro-inflammatory interleukins|Measure of trasforming growth factor (TGF-b)|Measure of tumor necrosis factor alpha (TNF-a)|Determining overexpression of pro-inflammatory selectin|Determining cell adhesion molecules (CAMs)|Measure of marker of oxidative stress PON-1
|
|
NCT05026801
|
Azithromycin Plus Hydroxychloroquine for COVID-19 Infection |
Withdrawn |
Phase 3 |
Feb/08/2021 |
Aug/26/2021 |
- Alternative id - IT005-501
- Interventions - Drug: Azithromycin plus hydroxychloroquine
- Study type - Interventional
- Study results - No Results Available
- Locations - Waterbury Hospial, Waterbury, Connecticut, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Microbiologic response|Combined clinical and microbiologic response
|
|
NCT04452617
|
Safety of Short-term Hydroxychloroquine Plus Azithromycin Treatment in Critically Ill Patients With Severe COVID-19 |
Completed |
|
Mar/19/2020 |
Jul/01/2020 |
- Alternative id - REA-03-2020
- Interventions -
- Study type - Observational
- Study results - No Results Available
- Locations - Institut Mutualiste Montsouris, Paris, France
- Study designs - Observational Model: Cohort|Time Perspective: Retrospective
- Enrollment - 40
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - occurrence of severe cardiac arrhythmia: torsade de pointes and cardiac arrest or sudden death|assessment of QTc interval prolongation during the treatment period compared to baseline ECG
|
|
NCT04411433
|
Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19 |
Active, not recruiting |
Phase 3 |
May/08/2020 |
Jun/01/2021 |
- Alternative id - COVID-19-FAV
- Interventions - Drug: Favipiravir (3200 mg + 1200 mg)|Drug: Favipiravir (3600 mg + 1600 mg)|Drug: Favipiravir (3200 mg + 1200 mg) combined with Hydroxychloroquine|Drug: Favipiravir (3200 mg + 1200 mg) combined with Azithromycin|Drug: Hydroxychloroquine|Drug: Hydroxychloroquine combined with Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Hacettepe University, School of Medicine, Ankara, Turkey
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 1008
- Age - 18 Years to 70 Years (Adult, Older Adult)
- Outcome measures - Time to recovery (discharge)|Decrease in viral load|Adverse Event (AE), Serious Adverse Event (SAE) and discontinuation of treatment|Frequency of occurrence of lymphopenia from baseline|Frequency of occurrence of thrombocytopenia from baseline|Changes in alanine aminotransferase (ALT) levels from baseline|Changes in aspartate aminotransferase (AST) levels from baseline|Changes in C-reactive protein (CRP) levels from baseline|Changes in level of D-dimer levels from baseline|Changes in prothrombin time (PT) values from baseline|Changes in partial thromboplastin time (PTT) values from baseline|Changes in blood pressure from baseline|Changes in respiratory rate from baseline|Changes in pulse oxymetry from baseline|Changes in fever from baseline
|
|
NCT04322396
|
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19 |
Terminated |
Phase 2 |
Apr/06/2020 |
Feb/02/2021 |
- Alternative id - KronLungesyg_COVID_19_protokol
- Interventions - Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo oral tablet
- Study type - Interventional
- Study results - Has Results
- Locations - Aalborg Sygehus, Aalborg, Denmark|Bispebjerg Hospital, Copenhagen, Denmark|Herlev-Gentofte Hospital, Copenhagen, Denmark|Hvidovre Hospital, Copenhagen, Denmark|Nordsjællands Hospital, Hillerød, Denmark|Odense Universitetshospital, Odense, Denmark|Roskilde Sygehus, Roskilde, Denmark|Slagelse Sygehus, Slagelse, Denmark
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 117
- Age - Child, Adult, Older Adult
- Outcome measures - Number of Days Alive and Discharged From Hospital Within 14 Days|Categorization of Hospitalization Status|Length of Stay in ICU|Number of Participants on Non-invasive Ventilation (NIV) During Hospitalization|Mortality|Length of Hospitalization|Days Alive and Discharged From Hospital|Number of Readmissions (All Causes)|Number of Days Using Non-invasive Ventilation (NIV)|Change in Patient's Oxygen Partial Pressure|Change in Patient's Carbondioxide Partial Pressure|Change of pH in Blood|Time for no Oxygen Supplement (or Regular Oxygen Supplement "LTOT")
|
|
NCT04334382
|
Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19 |
Recruiting |
Phase 3 |
Apr/02/2020 |
Dec/31/2021 |
- Alternative id - 1051360
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Intermountain Medical Center, Murray, Utah, United States|University of Utah, Salt Lake City, Utah, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 1550
- Age - 45 Years and older (Adult, Older Adult)
- Outcome measures - Hospitalization within 14 days of enrollment|Duration of COVID-19-attributable symptoms|Hospital-free days at 28 days|Ventilator-free days at 28 days|ICU-free days at 28 days
|
|
NCT04441424
|
Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients |
Completed |
Not Applicable |
Apr/03/2020 |
Jun/01/2020 |
- Alternative id - CPT-COVID-19
- Interventions - Biological: Convalescent plasma|Drug: Hydroxychloroquin with Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Akarkh Healt hdirectorate, Baghdad, Iraq
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 49
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Death versus survival of treated patients|The length of stay in hospitals
|
|
NCT04381936
|
Randomised Evaluation of COVID-19 Therapy |
Recruiting |
Phase 2|Phase 3 |
Mar/19/2020 |
Nov/01/2032 |
- Alternative id - NDPHRECOVERY|2020-001113-21|ISRCTN50189673
- Interventions - Drug: Lopinavir-Ritonavir|Drug: Corticosteroid|Drug: Hydroxychloroquine|Drug: Azithromycin|Biological: Convalescent plasma|Drug: Tocilizumab|Biological: Immunoglobulin|Drug: Synthetic neutralising antibodies|Drug: Aspirin|Drug: Colchicine|Drug: Baricitinib|Drug: Anakinra|Drug: Dimethyl fumarate|Drug: High Dose Corticosteroid|Drug: Empagliflozin|Drug: Sotrovimab
- Study type - Interventional
- Study results - No Results Available
- Locations - Kumasi Center for Collaborative Research in Tropical Medicine KNUST, Kumasi, Ghana|Indian Council of Medical Research, Division of Epidemiology and Communicable Diseases, New Delhi, India|Eijkman Oxford Clinical Research Unit (EOCRU), Eijkman Institute for Molecular Biology, Jakarta, Indonesia|Clinical Trial Unit, Oxford University Clinical Research Unit-Nepal, Patan Academy of Health Sciences, Kathmandu, Nepal|Wits Health Consortium, Johannesburg, South Africa|RECOVERY Sri Lanka & Pakistan, National Intensive Care Surveillance - M.O.R.U, Colombo, Sri Lanka|Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom|Oxford University Clinical Research Unit, Centre for Tropical Medicine, Ho Chi Minh City, Vietnam
- Study designs - Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 50000
- Age - Child, Adult, Older Adult
- Outcome measures - All-cause mortality|Duration of hospital stay|Composite endpoint of death or need for mechanical ventilation or ECMO
|
|
NCT04347512
|
EVALUATION OF THE EFFICACY OF THE HYDROXYCHLOROQUINE-AZITHROMYCIN COMBINATION IN THE IN THE PREVENTION OF COVID-19 RELATED SDRA |
Withdrawn |
Phase 3 |
Jun/02/2020 |
Jun/02/2020 |
- Alternative id - 7783
- Interventions - Drug: Hydroxychloroquine and azithromycin treatment arm.|Drug: Hydroxychloroquine|Drug: Control arm
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Rate of patients reaching a significant hypoxemia, in each arms.
|
|
NCT04358068
|
Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19 |
Terminated |
Phase 2 |
May/13/2020 |
Jul/08/2020 |
- Alternative id - ACTG A5395|38720
- Interventions - Drug: Hydroxychloroquine (HCQ)|Drug: Azithromycin (Azithro)|Drug: Placebo for Hydroxychloroquine|Drug: Placebo for Azithromycin
- Study type - Interventional
- Study results - Has Results
- Locations - Alabama CRS, Birmingham, Alabama, United States|UCSD Antiviral Research Center CRS, San Diego, California, United States|Harbor-UCLA CRS, Torrance, California, United States|Whitman-Walker Health CRS, Washington, District of Columbia, United States|Northwestern University CRS, Chicago, Illinois, United States|Rush University CRS, Chicago, Illinois, United States|Greensboro CRS, Greensboro, North Carolina, United States|Cincinnati Clinical Research Site, Cincinnati, Ohio, United States|University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States|Trinity Health and Wellness Center CRS, Dallas, Texas, United States|University of Washington AIDS CRS, Seattle, Washington, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
- Enrollment - 20
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Number of Participants Who Died From Any Cause or Were Hospitalized|Number of Participants Who Died From Any Cause|Number of Participants Who Died From Any Cause, or Were Hospitalized, or Had an Urgent Visit to Emergency Room or Clinic|Number of Participants Who Died From Any Cause or Were Hospitalized Through the End of Follow-up|Number of Participants Who Prematurely Discontinue Study Treatment Due to an Adverse Event|Number of Participants Who Had Any Cardiac Adverse Events|Duration of Fever|Duration of Symptoms Associated With COVID-19 Disease|Participant-specific Area Under the Curve (AUC) of the Symptom Score Associated With COVID-19 Disease Over Time|Time to Self-reported Return to Usual (Pre-COVID) Health.|SARS-CoV-2 RNA Detection Status From Self-collected Nasal and Site-collected NP Swabs Among Subset|SARS-CoV-2 RNA Level (Continuous) From Self-collected Nasal and Site-collected NP Swabs Among Subset|Number of Participants With an Occurrence of Fainting
|
|
NCT04359316
|
Azithromycin in Hospitalized COVID-19 Patients |
Not yet recruiting |
Phase 4 |
Apr/20/2020 |
May/05/2020 |
- Alternative id - Azithromycin in COVID-19
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Shahid Modarres Hospital, Shahid Beheshti University of Medical Sciences and Health Services, Tehran, Iran, Islamic Republic of
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 40
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Time to clinical improvement|Mortality|SpO2 Improvement|Incidence of new mechanical ventilation use|Duration of hospitalization|Cumulative incidence of serious adverse events
|
|
NCT04613271
|
Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia |
Recruiting |
Phase 3 |
Oct/15/2020 |
Dec/30/2021 |
- Alternative id - FVR|U1111-1263-1797
- Interventions - Drug: Favipiravir|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - RSJ Soerodjo, Magelang, Central Java, Indonesia|RSUP Dr. Kariadi, Semarang, Central Of Java, Indonesia|RSPI Sulianti Saroso, Jakarta, DKI Jakarta, Indonesia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 210
- Age - 18 Years to 59 Years (Adult)
- Outcome measures - Clinical improvement measured by no sign & symptom for 3 days and RTPCR negative|Duration of hospitalization
|
|
NCT04673214
|
Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment |
Completed |
Phase 3 |
Dec/16/2020 |
Feb/25/2021 |
- Alternative id - R-2020-785-176
- Interventions - Drug: Azithromycin / Ivermectin / Ribaroxaban / Paracetamol|Drug: Azithromycin / Ribaroxaban / Paracetamol
- Study type - Interventional
- Study results - Has Results
- Locations - Alma Italia Guerrero Martinez, Mexico, Distrito Federal, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
- Enrollment - 114
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Average Days in COVID-19 Symptoms by Type of Therapy in the UMF 20 and UMF 13 of the IMSS.|Crosstabulated Outcome in Modification of the Evolution Clinical vs Fails Therapeutic by Type of Treatment in Patients With COVID-19 UMF 13 and UMF 20 of the IMSS
|
|
NCT04339816
|
Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial |
Terminated |
Phase 3 |
May/13/2020 |
Nov/04/2020 |
- Alternative id - AZIQUINE-ICU-25032020|2020-001456-18
- Interventions - Drug: Azithromycin|Drug: Hydroxychloroquine|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - František Duška, Praha, Česká Republika, Czechia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 3
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Proportion of alive patients free off mechanical ventilation|Proportion of patients who avoided the need of mechanical ventilation|ICU LOS|Mortality28|Mortality90
|
|
NCT04405921
|
Hydroxychloroquine, Azithromycin in the Treatment of Covid-19 |
Not yet recruiting |
Phase 3 |
Jul/01/2020 |
Mar/01/2021 |
- Alternative id - PACTT
- Interventions - Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 250 MG
- Study type - Interventional
- Study results - No Results Available
- Locations - University Hospital Farhat Hached, Sousse, Tunisia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Clinical recovery at day-14, from the start of treatment.|Viral Clearance via RT-PCR at day 5- 7-10 and day 14
|
|
NCT04370782
|
Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting |
Completed |
Phase 4 |
Apr/28/2020 |
Sep/30/2020 |
- Alternative id - 20-21
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Zinc Sulfate|Drug: Doxycycline
- Study type - Interventional
- Study results - No Results Available
- Locations - St Francis Hospital, Roslyn, New York, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 18
- Age - 30 Years and older (Adult, Older Adult)
- Outcome measures - Time to Resolution of Symptoms relative to baseline (day 1 of trial)|Number of participants hospitalized and/or requiring repeat ER visits|ICU Length of Stay|Ventilator|Severity of symptoms|Number of participants with adverse events due to drug regimen|Number of participants with QTc prolongation >500ms
|
|
NCT04345861
|
Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial) |
Terminated |
Phase 2|Phase 3 |
Apr/11/2020 |
Apr/09/2021 |
- Alternative id - RECHMPL20_168
- Interventions - Drug: Hydroxychloroquine + placebo|Drug: hydroxychloroquine + azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Montpellier University hospital, Montpellier, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
- Enrollment - 7
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Time to clinical improvement of at least 1 level on the ordinal scale between Day 1 (day of the first administration of study drug) to Day 11 (day after last day of treatment).|Clinical status assessed by ordinal scale|transfer to ICU|Length of hospital day|Hospital Mortality|Need to Mechanical Ventilation|Occurence of grade 3-4 adverse event|QTc Lengthening|Evolution of pulmonary CT scan images
|
|
NCT04374552
|
Asymptomatic COVID-19 Trial |
Withdrawn |
Phase 2 |
May/05/2020 |
Apr/01/2021 |
- Alternative id - Pro2020000872
- Interventions - Drug: Hydroxychloroquine sulfate &Azithromycin|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Robert Wood Johnson University Hospital, New Brunswick, New Jersey, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 20 Years and older (Adult, Older Adult)
- Outcome measures - The primary outcome is the rate of decline in viral load over the 10 days after randomization
|
|
NCT04354428
|
Treatment for COVID-19 in High-Risk Adult Outpatients |
Active, not recruiting |
Phase 2|Phase 3 |
Apr/16/2020 |
Jan/01/2021 |
- Alternative id - STUDY00009878|INV-017062
- Interventions - Drug: Ascorbic Acid|Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Folic Acid|Drug: Lopinavir 200 MG / Ritonavir 50 MG [Kaletra]
- Study type - Interventional
- Study results - No Results Available
- Locations - Ruth M. Rothstein CORE Center - Cook County Health, Chicago, Illinois, United States|Tulane University, New Orleans, Louisiana, United States|Boston University, Boston, Massachusetts, United States|SUNY Upstate Medical University, Syracuse, New York, United States|University of Washington Coordinating Center, Seattle, Washington, United States|UW Virology Research Clinic, Seattle, Washington, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
- Enrollment - 300
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - Lower respiratory tract infection (LRTI) rates|Incidence of hospitalization or mortality|Change in upper respiratory viral shedding|COVID-19 symptom resolution rates [Lopinavir-ritonavir arm only]|Rate of participant-reported adverse events|COVID-19-related hospitalization days|Rate of disease severity|Viral shedding rates|Individual lopinavir-ritonavir concentration profiles and exposure estimates [Lopinavir-ritonavir arm only]
|
|
NCT04351919
|
Assessment of Efficacy and Safety of HCQ and Antibiotics Administrated to Patients COVID19(+) |
Withdrawn |
Phase 4 |
May/05/2020 |
Jul/15/2020 |
- Alternative id - ECC2020-04
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Eshmoun Clinical Research Centre/ Hôpital Abderrahmen Mami-Ariana, Tunis, Tunisia
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - improvment or healing of clinical signs|Evolution of clinical signs
|
|
NCT04371107
|
Proactive Care of Ambulatory COVID19 Patients |
Not yet recruiting |
Phase 3 |
Apr/29/2020 |
Jul/01/2020 |
- Alternative id - PI2020_843_0039
- Interventions - Other: consultation|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - CHU Amiens, Amiens, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 64
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Length of symptom duration (in days) with azithromycin treatment
|
|
NCT04359953
|
Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19 |
Recruiting |
Phase 3 |
Apr/25/2020 |
Apr/01/2022 |
- Alternative id - 7747
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Telmisartan
- Study type - Interventional
- Study results - No Results Available
- Locations - CHU de Strasbourg, Strasbourg, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 1600
- Age - 60 Years and older (Adult, Older Adult)
- Outcome measures - Two-weeks survival rate|Rate of undetectable RT-PCR of SARS-CoV-2|Rate of death|Hypotension|Hypothermia and hyperthermia|Pneumonia severity according to WHO|Pneumonia severity according to PSI (Hung et al 2017)|Rate of no cough|Rate of no dyspnea|Rate of no fever|Rate of no requiring supplemental oxygen|Rate of SARS-Cov-2 undetectable|Recovery time|Critical admission rate|Mechanical ventilation rate|Changes in Activity of Daily Living (ADL) Activity of Daily Living)|Changes in Activity of Daily Living IADL (Instrumental Activity of Daily Living)|The number and dose of added corticosteroids, immonumodulators or immunosuppressants
|
|
NCT04434144
|
A Comparative Study on Ivermectin and Hydroxychloroquine on the COVID19 Patients in Bangladesh |
Completed |
|
May/02/2020 |
Jun/05/2020 |
- Alternative id - 10000918
- Interventions - Drug: Ivermectin + Doxycycline|Drug: Hydroxychloroquine + Azithromycin
- Study type - Observational
- Study results - No Results Available
- Locations - Chakoria Upazilla Health Complex, Cox's Bazar, Bangladesh
- Study designs - Observational Model: Case-Only|Time Perspective: Prospective
- Enrollment - 116
- Age - 16 Years to 80 Years (Child, Adult, Older Adult)
- Outcome measures - Number of participants with "treatment success" determine by a negative RT PCR for COVID19.|Number of participants with "adverse effects" determined by the existence of the pharmacological side effects of the particular drug during treatment.
|
|
NCT04355052
|
Open Label Study to Compare Efficacy, Safety and Tolerability of Hydroxychloroquine Combined With Azithromycin Compared to Hydroxychloroquine Combined With Camostat Mesylate and to "no Treatment" in SARS CoV 2 Virus |
Recruiting |
Phase 3 |
Apr/11/2020 |
Dec/11/2020 |
- Alternative id - 7092-20-SMC
- Interventions - Drug: hydroxychloroquine in combination with camostat mesylate|Drug: Hydroxychloroquine in combination of Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Sheba Medical Center, Ramat Gan, Israel|Sheba Medical Center, Tel HaShomer, Israel
- Study designs - Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 250
- Age - 18 Years to 120 Years (Adult, Older Adult)
- Outcome measures - clinical state as reflected by NEWS scoring|positive PCR|prevention of ICU|prevention of assisted ventilation|prevention of ECMO|death
|
|
NCT04381962
|
A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2) |
Completed |
Phase 3 |
Jun/03/2020 |
Apr/20/2021 |
- Alternative id - ATOMIC2|2020-001740-26|282892|20/HRA/2105
- Interventions - Drug: Azithromycin Capsule
- Study type - Interventional
- Study results - No Results Available
- Locations - Horton General Hospital, Banbury, Oxfordshire, United Kingdom|John Radcliffe Hospital, Oxford, Oxfordshire, United Kingdom|Ninewells Hospital, Dundee, Scotland, United Kingdom|Birmingham City Hospital, Birmingham, United Kingdom|Sandwell General Hospital, West Bromwich, United Kingdom
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 298
- Age - 19 Years and older (Adult, Older Adult)
- Outcome measures - Proportion progressing to respiratory failure or death (all clinically-diagnosed participants)|Proportion progressing to respiratory failure or death (SARS-CoV-2 PCR positive)|All cause mortality|Proportion progressing to pneumonia.|Proportion progressing to severe pneumonia|Peak severity of illness|Safety and tolerability
|
|
NCT04348474
|
Efficacy and Safety of Hydroxychloroquine and Azithromycin for the Treatment of Ambulatory Patients With Mild COVID-19 |
Suspended |
Early Phase 1 |
Apr/20/2020 |
Jul/31/2020 |
- Alternative id - HIAPRE0420OR
- Interventions - Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin Tablets
- Study type - Interventional
- Study results - No Results Available
- Locations - Prevent Senior Private Operadora de Saúde LTDA., São Paulo, Brazil
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Change in Clinical Condition|Hospitalization|Rate of mortality within 28-days|Change in Clinical Condition related to comorbidity
|
|
NCT04344457
|
Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19 |
Recruiting |
Phase 1|Phase 2 |
Apr/16/2020 |
Sep/30/2020 |
- Alternative id - HIZ-PRC-COVID-19
- Interventions - Drug: Hydroxychloroquine|Drug: Indomethacin|Drug: Zithromax Oral Product
- Study type - Interventional
- Study results - No Results Available
- Locations - Perseverance Research Center, Scottsdale, Arizona, United States|Covidcraz 19, Llc, New Orleans, Louisiana, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 80
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Improvement of clinical status|Time of clinical recovery of fever|Time of clinical recovery of cough|Safety as determined by changes in QTC intervals measured by ECG|Safety as determined by presence of side effects|Time to improvement
|
|
NCT04328272
|
Effectiveness of Hydroxychloroquine in Covid-19 Patients |
Unknown status |
Phase 3 |
Mar/28/2020 |
Jun/28/2020 |
- Alternative id - Ath/ct101/22/3
- Interventions - Drug: Hydroxychloroquine 200 Mg Oral Tablet|Drug: Azithromycin 500Mg Oral Tablet|Dietary Supplement: Glucose tablets
- Study type - Interventional
- Study results - No Results Available
- Locations - Ayub Teaching Institution, Abbottābād, K.p.k, Pakistan
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
- Enrollment - 75
- Age - 18 Years to 50 Years (Adult)
- Outcome measures - National Early Warning Score equal to zero|C-reactive proteins|Lymphocyte Count|d-dimers
|
|
NCT04332094
|
Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19) |
Recruiting |
Phase 2 |
Apr/02/2020 |
Jul/01/2021 |
- Alternative id - IIBSP-COV-2020-23
- Interventions - Drug: Tocilizumab|Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain|Hospital General Universitario de Alicante, Alicante, Valencia, Spain|Hospital General Universitario de Elche, Elche, Valencia, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Hospital del Mar, Barcelona, Spain|Hospital Sant Joan Despí, Barcelona, Spain|Hospital Clinico San Carlos, Madrid, Spain
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 276
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - In-hospital mortality|Need for mechanical ventilation in the Intensive Care Unit
|
|
NCT04332107
|
Azithromycin for COVID-19 Treatment in Outpatients Nationwide |
Terminated |
Phase 3 |
May/22/2020 |
Mar/30/2021 |
- Alternative id - 20-30504
- Interventions - Drug: Azithromycin|Drug: Placebos
- Study type - Interventional
- Study results - Has Results
- Locations - University of California San Francisco, San Francisco, California, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 263
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Number of Participants Who Were Symptom Free at Day 14|Viral Load|Mortality|Adverse Events|Positive SARS-CoV-2 Test - Nasal Swab|Positive SARS-CoV-2 Test - Saliva Swab|Positive SARS-CoV-2 Test - Rectal Swab|Genetic Macrolide Resistance Determinants|Secondary Outcomes Through Day 21|Number of Participants With Emergency Room Visits|Number of Household Members With COVID-19 (Confirmed or Symptomatic)|Number of Participants That Died|Number of Participants Reporting Hospitalization
|
|
NCT04395768
|
International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 |
Recruiting |
Phase 2 |
Sep/09/2020 |
Dec/31/2021 |
- Alternative id - Alliance-COVID19
- Interventions - Dietary Supplement: Vitamin C|Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Zinc Citrate|Dietary Supplement: Vitamin D3|Dietary Supplement: Vitamin B12
- Study type - Interventional
- Study results - No Results Available
- Locations - National Institute of Integrative Medicine, Melbourne, Victoria, Australia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 200
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Symptoms|Length of hospital stay|invasive mechanical ventilation or mortality|Mortality|mechanical ventilation|oxygen|ICU|days in hospital|days in ICU|renal replacement therapy|Extracorporeal support
|
|
NCT04349592
|
Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19 |
Completed |
Not Applicable |
Apr/14/2020 |
Aug/30/2020 |
- Alternative id - MRC-05-001
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Other: Placebo Tablet|Other: Placebo capsules
- Study type - Interventional
- Study results - No Results Available
- Locations - Hamad Medical Corporation, Doha, Qatar
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 456
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Proportion of virologically cured (PCR-negative status) as assessed on day six|virologic cure on other study days|virologic semiquantitative analysis of changing viral load|proportion of initially symtomatic subjects with disappearance of clinical symptoms|proportion of initially asymtomatic subjects with appearance of new clinical symptoms|proportions of subjects with potentially medication- related adverse events
|
|
NCT04964583
|
Hidroxicloroquina With Azitromicina Versus Hidroxicloroquina and Placebo Int Patients With Mild COVID-19 |
Recruiting |
Phase 2|Phase 3 |
Jan/20/2021 |
Aug/01/2021 |
- Alternative id - 2020-785-138
- Interventions - Drug: Hydroxychloroquine with Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - UMF 28, Benito Juárez, Mexico City, Mexico|Fundación IMSS, Cuauhtémoc, Mexico City, Mexico|UMF 52, Cuautitlán Izcalli, State Of Mexico, Mexico
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 105
- Age - 18 Years to 75 Years (Adult, Older Adult)
- Outcome measures - Hospitalization|Viral load|Clinical safety
|
|
NCT04458948
|
Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients |
Active, not recruiting |
Phase 2 |
Mar/24/2020 |
Mar/24/2025 |
- Alternative id - 20-156
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - University of New Mexico Health Sciences Center, Albuquerque, New Mexico, United States
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 10000
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Duration of viral shedding|Evaluation of Fatality Rate|Evaluation of Clinical Response|Evaluation of Length of Hospital Stay
|
|
NCT04358081
|
Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease |
Completed |
Phase 3 |
May/01/2020 |
Jul/27/2020 |
- Alternative id - CJWT629A12301
- Interventions - Drug: HCQ|Drug: HCQ+AZT|Drug: Placebo
- Study type - Interventional
- Study results - Has Results
- Locations - Novartis Investigative Site, Fullerton, California, United States|Novartis Investigative Site, Los Angeles, California, United States|Novartis Investigative Site, Chicago, Illinois, United States|Novartis Investigative Site, Baton Rouge, Louisiana, United States|Novartis Investigative Site, Baltimore, Maryland, United States|Novartis Investigative Site, Chapel Hill, North Carolina, United States|Novartis Investigative Site, Seattle, Washington, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 20
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Number of Participants Who Achieved Clinical Response by Day 15|Number of Participants Who Achieved Viral Clearance|Number of Participants Discharged or Ready for Discharge|Time to Return to Pre-morbid Supplemental Oxygen Requirement in Participants Receiving Hydrochloroquine or Hydrochloroquine Plus Azithromycin Relative to Placebo
|
|
NCT04590274
|
Safety and Efficacy of Hydroxychloroquine for the Treatment & Prevention of Coronavirus Disease 2019 (COVID-19) Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) |
Withdrawn |
Phase 1 |
Nov/01/2020 |
Dec/01/2021 |
- Alternative id - CTP-HCQ-COVID19
- Interventions - Drug: Hydroxychloroquine|Dietary Supplement: Vitamins and Minerals|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
- Enrollment - 0
- Age - Child, Adult, Older Adult
- Outcome measures - Percentage of individuals who develop COVID-19 symptoms
|
|
NCT04336332
|
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19 |
Active, not recruiting |
Phase 2 |
Apr/01/2020 |
Jun/30/2022 |
- Alternative id - Pro2020000712|002011
- Interventions - Combination Product: Hydroxychloroquine Sulfate + Azithromycin|Drug: Hydroxychloroquine Sulfate
- Study type - Interventional
- Study results - No Results Available
- Locations - Saint Barnabas Medical Center, Livingston, New Jersey, United States|Robert Wood Johnson University Hopsital, New Brunswick, New Jersey, United States|Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States|The University Hospital, Newark, New Jersey, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 160
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Changes in patients viral load|Second evaluation of changes in patients viral load|Symptom questionnaire|Fever assessment|Vital Signs - Body Temperature|Discharge|Recovery|Assessment of agent toxicity|Oropharynx swab sample collections|Blood Sample collections|Viral shedding assessment - nasopharyngeal secretions|Viral shedding assessment - serology|Cytokines in blood
|
|
NCT04338698
|
Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT |
Completed |
Phase 3 |
Apr/22/2020 |
Nov/22/2020 |
- Alternative id - 12(06)/2016-Coord
- Interventions - Drug: Hydroxychloroquine|Drug: Oseltamivir|Drug: Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Faislabad Medical University, Faisalābad, Pakistan|Gujranwala Medical College, Gujrānwāla, Pakistan|Nawaz Sharif Medical College, Gujrāt, Pakistan|Szabmu-Pims, Islamabad, Pakistan|Akram Medical Complex, Lahore, Pakistan|Fatima Jinnah Medical University, Lahore, Pakistan|King Edward Medical University-Mayo Hospital, Lahore, Pakistan|Lahore General Hospital, Lahore, Pakistan|Khyber Teaching Hospital, Peshawar, Pakistan|Rawalpindi Medical University, Rawalpindi, Pakistan|Sargodha Medical College, Sargodha, Pakistan
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 550
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Laboratory Result|Clinical Outcome
|
|
NCT04383717
|
Levamisole and Isoprinosine in the Treatment of COVID19: A Proposed Therapeutic Trial |
Not yet recruiting |
Phase 3 |
May/05/2020 |
Oct/30/2020 |
- Alternative id - Levamisole and isoprinosine
- Interventions - Drug: Levamisole and isoprinosine|Drug: Azithromycin and hydroxychloroquine
- Study type - Interventional
- Study results - No Results Available
- Locations -
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 60
- Age - 6 Years to 90 Years (Child, Adult, Older Adult)
- Outcome measures - COVID 19 induced fever in both groups|COVID 19 induced dyspnea in both groups|COVID 19 viral load in both groups|laboratory clearance in both groups: CRP in mg/dL
|
|
NCT04459702
|
A Study of Combination Therapies to Treat COVID-19 Infection |
Withdrawn |
Phase 2 |
Jul/01/2020 |
Dec/01/2021 |
- Alternative id - PRG-043
- Interventions - Drug: hydroxychloroquine|Drug: Azithromycin|Drug: Ritonavir|Drug: Lopinavir
- Study type - Interventional
- Study results - No Results Available
- Locations - ProgenaBiome, Ventura, California, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years to 65 Years (Adult, Older Adult)
- Outcome measures - Efficacy of Treatment by Reduced Symptoms NEWS (National Early Warning System) scores|Efficacy of Treatment by Time to Non-Infectivity|Safety of Dual Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) sores|Safety of Quadruple Therapy as Measured by Symptoms rated on the NEWS (National Early Warning System) scores.|Safety of Dual Therapy as Measured by Complete Blood Count|Safety of Quadruple Therapy as Measured by Complete Blood Count|Safety of Dual Therapy as Measured by Metabolic Panel -Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Albumin|Safety of Quadruple Therapy as Measured by Metabolic Panel - A/G Ratio|Safety of Dual Therapy as Measured by Metabolic Panel A/G Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel Alkaline Phosphatase|Safety of Dual Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - AST|Safety of Quadruple Therapy as Measured by Metabolic Panel - ALT|Safety of Dual Therapy as Measured by Metabolic Panel ALT|Safety of Dual Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel BUN/Creatinine Ratio|Safety of Quadruple Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - BUN|Safety of Dual Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Calcium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Carbon Dioxide|Safety of Dual Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Chloride|Safety of Quadruple Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Creatinine|Safety of Dual Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Globulin|Safety of Quadruple Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Glucose|Safety of Dual Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Potassium|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Bilirubin|Safety of Dual Therapy as Measured by Metabolic Panel - Total Protein|Safety of Quadruple Therapy as Measured by Metabolic Panel - Total Protein|Safety of Dual Therapy as Measured by Treatment Related SAE|Safety of Quadruple Therapy as Measured by Treatment Related SAE
|
|
NCT04322123
|
Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19) |
Active, not recruiting |
Phase 3 |
Apr/01/2020 |
Aug/30/2021 |
- Alternative id - Brazil COVID Coalition I Trial
- Interventions - Drug: Hydroxychloroquine Oral Product|Drug: Hydroxychloroquine + azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital Geral Clériston Andrade, Feira De Santana, BA, Brazil|Hospital Ana Nery - HAN/SESAB, Salvador, BA, Brazil|HHospital SAMUR, Vitória Da Conquista, BA, Brazil|Hospital Geral de Vitória da Conquista, Vitória Da Conquista, BA, Brazil|Hospital de Brasília, Brasilia, DF, Brazil|Instituto de Cardiologia do Distrito Federal, Brasília, DF, Brazil|Hospital Maternidade São José - UNESC - Fundação Social Rural de Colatina, Colatina, ES, Brazil|Hospital Vila da Serra, Nova Lima, MG, Brazil|Santa Casa de Misericórdia de São João Del Rei, São João Del Rei, MG, Brazil|Associação Evangélica Beneficente de Londrina - Hospital Evangélico de Londrina, Londrina, PR, Brazil|Instituto Estadual do Cérebro Paulo Niemeyer, Rio De Janeiro, RJ, Brazil|Hospital Geral de Caxias do Sul, Caxias do Sul, RS, Brazil|Hospital Santa Rita - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São Francisco - Irmandade Santa Casa de Porto Alegre, Porto Alegre, RS, Brazil|Hospital São José, Criciuma, SC, Brazil|Hospital Baía Sul - Baía Sul Medical Center, Florianópolis, SC, Brazil|Hospital Nereu Ramos, Florianópolis, Sc, Brazil|Centro Hospitalar Unimed, Joinville, SC, Brazil|Hospital de Amor - Unidade Barretos (Fundação PIO XII), Barretos, SP, Brazil|Casa de Saúde Santa Marcelina, São Paulo, SP, Brazil|Hospital Albert Einstein, São Paulo, SP, Brazil|Hospital Beneficência Portuguesa - Real e Benemérita Associação Portuguesa de Beneficência, São Paulo, SP, Brazil|Hospital BP Mirante - Real e Benemérita, São Paulo, SP, Brazil|Hospital das Clínicas da FMUSP, São Paulo, SP, Brazil|Hospital do Servidor Público Estadual - HSPE - IAMSPE, São Paulo, SP, Brazil|Hospital São Paulo - UNIFESP, São Paulo, SP, Brazil|Hospital Sírio-Libanês, São Paulo, SP, Brazil|Hospital SEPACO, São Paulo, S, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 630
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Evaluation of the clinical status|Ordinal scale in 7 days|Need of intubation and mechanical ventilation|Use of mechanical ventilation during hospital stay|Use of non-invasive ventilation|Hospital Length of Stay|All-cause mortality|Thromboembolic complications|Acute renal disfunction|Number of days alive and free of respiratory support up to 15 days
|
|
NCT04363060
|
Azithromycin+Amoxicillin/Clavulanate vs Amoxicillin/Clavulanate in COVID19 Patients With Pneumonia in Non-intensive Unit |
Not yet recruiting |
Phase 3 |
Apr/30/2020 |
Jul/30/2020 |
- Alternative id - RC20_0168
- Interventions - Combination Product: Azithromycin with amoxicillin/clavulanate|Drug: amoxicillin/clavulanate
- Study type - Interventional
- Study results - No Results Available
- Locations - Chu Angers, Angers, France|CHD Vendée, La Roche-sur-Yon, France|CHU Poitiers, Poitiers, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 104
- Age - 18 Years to 99 Years (Adult, Older Adult)
- Outcome measures - Rate of positive SARS-CoV-2 RT-PCR|Clinical evolution on the World Health Organization Ordinal Scale for Clinical Improvement for COVID-19|Total duration of antibiotic treatment during the 30 days following inclusion|Number of all-cause mortality during the 30 days following inclusion|Number of in-hospital mortality during the 30 days following inclusion|Number of patients transferred to intensive care unit during the 30-day follow-up|Number of days without mechanical ventilation during the 30 days following inclusion|adverse events attributable to antibiotic treatment during the 30 days following inclusion|Hospital length of stay during the 30 days following inclusion
|
|
NCT04341727
|
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection |
Terminated |
Phase 3 |
Apr/04/2020 |
Apr/01/2021 |
- Alternative id - 202003188
- Interventions - Drug: Hydroxychloroquine Sulfate|Drug: Azithromycin|Drug: Chloroquine Sulfate
- Study type - Interventional
- Study results - No Results Available
- Locations - Washington University School of Medicine Infectious Disease Clinical Research Unit, Saint Louis, Missouri, United States|Washington University School of Medicine, Saint Louis, Missouri, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 31
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Hours to recovery|Time fever resolution
|
|
NCT04390152
|
Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19 |
Recruiting |
Phase 1|Phase 2 |
Jan/13/2020 |
Apr/01/2022 |
- Alternative id - BIOXSOMCOV001
- Interventions - Drug: Wharton's jelly derived Mesenchymal stem cells.|Drug: Hydroxychloroquine, lopinavir/ritonavir or azithromycin and placebo (standard therapy)
- Study type - Interventional
- Study results - No Results Available
- Locations - BioXcellerator, Medellin, Antioquia-CO, Colombia|Clinical Somer, Rionegro, Antioquia, Colombia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 40
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - Intergroup mortality difference with treatment|Number of patients with treatment related adverse events|Difference in days of mechanical ventilation between groups|Median reduction of days of hospitalization|Median reduction of days of oxygen needs|Difference between "Sequential Organ Failure Assessment" score between groups|Difference between median Murray score between groups|Difference in APACHE II score between groups|Difference in lymphocyte count between groups|Changes in C reactive protein concentration between groups|Changes in D dimer concentration|Changes in ferritin concentration|Changes in lactate dehydrogenase concentration|Impact on interleukin 6 concentrations between groups.|Impact on interleukin 8 concentrations between groups.|Impact on interleukin 10 concentrations between groups.|Impact on tumor necrosis factor alpha concentrations between groups.
|
|
NCT04366089
|
Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora |
Recruiting |
Phase 2 |
Mar/26/2020 |
Dec/31/2020 |
- Alternative id - 110/2020
- Interventions - Other: Oxygen-ozone therapy, probiotic supplementation and Standard of care|Dietary Supplement: SivoMixx (200 billion)|Drug: Azithromycin|Drug: hydroxychloroquine
- Study type - Interventional
- Study results - No Results Available
- Locations - Francesco Pugliese, Rome, RM, Italy
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 152
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Delta in the number of patients requiring orotracheal intubation despite treatment|Delta of crude mortality|Delta of length of stay for patients in hospital|delta in the value of interleukin (IL)-1|delta in the value of IL-6|delta in the value of IL-10|delta in the value of Tumor Necrosis Factor (TNF)-alpha|delta in the value of cluster of differentiation (CD)4+ CD38/ Human Leukocyte Antigen-DR isotype (HLA-DR)|delta in the value of CD8+ CD38/ HLA-DR|delta in the value of fecal calprotectin|delta in the value of lipopolysaccharide (LPS)|delta in the value of zonulin|delta in the value of alpha1-antitrypsin
|
|
NCT03871491
|
Azithromycin-Prevention in Labor Use Study (A-PLUS) |
Recruiting |
Phase 3 |
Sep/01/2020 |
Sep/01/2023 |
- Alternative id - CP Azithromycin
- Interventions - Drug: Azithromycin|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - ICDDRB, Dhaka, Bangladesh|Kinshasa School of Public Health, Kinshasa, Congo, The Democratic Republic of the|Institute for Nutrition of Central America and Panama (INCAP), Guatemala City, Guatemala|Jawaharlal Nehru Medical College, Belagavi, India|Lata Medical Research Foundation, Nagpur, India|Moi University School of Medicine, Eldoret, Kenya|The Aga Khan University, Karachi, Pakistan|University Teaching Hospital, Lusaka, Zambia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention
- Enrollment - 34000
- Age - 18 Years to 45 Years (Adult)
- Outcome measures - Maternal: Incidence of maternal death or sepsis within 6 weeks (42 days) post-delivery in intervention vs. placebo group.|Neonatal: Incidence of intrapartum/neonatal death or sepsis within 4 weeks (28 days) post-delivery in intervention vs. placebo group|Incidence of chorioamnionitis|Incidence of endometritis|Incidence of other infections|Incidence of use of subsequent maternal antibiotic therapy|Maternal initial hospital length of stay|Incidence of maternal readmissions|Incidence of maternal admission to special care units|Incidence of maternal unscheduled visit for care|Incidence of maternal GI symptoms|Incidence of maternal death due to sepsis|Incidence of other neonatal infections (e.g. eye infection, skin infection)|Neonatal initial hospital length of stay|Incidence of neonatal readmissions|Incidence of neonatal admission to special care units|Incidence of neonatal unscheduled visit for care|Incidence of neonatal death due to sepsis|Incidence of pyloric stenosis within 42 days of delivery
|
|
NCT04575558
|
HOPE: A Trial of Hydroxichloroquine Plus Azithromycin in High Risk COVID-19 |
Withdrawn |
Phase 2 |
Jun/30/2020 |
Oct/30/2020 |
- Alternative id - LACOG 0220
- Interventions - Drug: Hydroxychloroquine and Azithromycin
- Study type - Interventional
- Study results - No Results Available
- Locations - Núcleo de Oncologia da Bahia - NOB, Salvador, BA, Brazil|Oncoclínicas BH, Belo Horizonte, MG, Brazil|Centro Oncológico do Triângulo - COT, Uberlândia, MG, Brazil|Multihemo, Recife, PE, Brazil|Oncoclinicas RJ, Rio De Janeiro, RJ, Brazil|Centro de Pesquisa em Oncologia PUCRS, Porto Alegre, RS, Brazil|Centro Paulista de Oncologia, São Paulo, SP, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Clinical deterioration rate|Mortality and cause of death|Incidence and type of Adverse Events (EAs)|Incidence and type of Serious Adverse Events (SAE)|Discontinuation rate or temporary suspension of treatment|Descriptive radiologic changes on chest CT scans
|
|
NCT04528927
|
Evaluation of the Efficacy and Safety of Treatments for Patients Hospitalized for COVID-19 Infection Without Signs of Acute Respiratory Failure, in Tunisia |
Withdrawn |
Phase 3 |
May/15/2020 |
Jul/15/2020 |
- Alternative id - ECC2020-05
- Interventions - Drug: HCQ|Drug: Azithromycin|Drug: Doxycycline|Dietary Supplement: Zinc
- Study type - Interventional
- Study results - No Results Available
- Locations - Eshmoun Clinical Research Centre, Tunis, Tunisia
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years to 80 Years (Adult, Older Adult)
- Outcome measures - Evaluate the rate of patients cured at the end of the study.|Evaluate the rate of patients are pauci-symptomatic at the end of the study.|Evaluate the rate of patients with worsening clinical signs
|
|
NCT04347031
|
A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19 |
Completed |
Phase 2|Phase 3 |
Apr/08/2020 |
Nov/20/2020 |
- Alternative id - FL-01/20
- Interventions - Drug: Mefloquine|Drug: Hydroxychloroquine|Combination Product: Mefloquine + azithromycin + / - tocilizumab|Combination Product: Hydroxychloroquine + azithromycin + / - tocilizumab
- Study type - Interventional
- Study results - No Results Available
- Locations - Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
- Enrollment - 320
- Age - 18 Years to 60 Years (Adult)
- Outcome measures - 1st primary endpoint for group 1|2nd primary endpoint for group 1|1st primary endpoint for group 2|2nd primary endpoint for group 2|1st secondary endpoint for group 1|2nd secondary endpoint for group 1|3d secondary endpoint for group 1|4th secondary endpoint for group 1|5th secondary endpoint for group 1|6th secondary endpoint for group 1|1st secondary endpoint for group 2|2nd secondary endpoint for group 2|3d secondary endpoint for group 2|4th secondary endpoint for group 2|5th secondary endpoint for group 2|6th secondary endpoint for group 2
|
|
NCT04729491
|
EAT-DUTA AndroCoV Trial |
Completed |
Phase 2|Phase 3 |
Jun/30/2020 |
Oct/07/2020 |
- Alternative id - CORPO-AB-DRUG-SARS-004B
- Interventions - Drug: Dutasteride 0.5 mg|Drug: Azithromycin|Drug: Nitazoxanide|Drug: Placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Corpometria Institute, Brasília, DF, Brazil
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
- Enrollment - 138
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Positivity rate of rtPCR-SARS-CoV-2 (qualitative analysis)|World Health Organization (WHO) Clinical Progression Scale [0 to 10; 0 = uninfected; 10 = death]|World Health Organization (WHO) COVID=19 Ordinal Scale for Clinical Improvement [1 to 8; 1 = not hospitalized, no limitation on activities; 8 = death]|Time-to-recovery|SARS-CoV-2 viral load|Duration of fatigue|Duration of anosmia|Overall duration of clinical manifestations|Proportion of subjects needing additional drugs or interventions|Proportion of subjects needing oxygen use|Proportion of subjects needing high-flow oxygen therapy or non-invasive ventilation|Proportion of hospitalizations|Proportion of mechanical ventilation use|Proportion of vasopressors use|Proportion of deaths|Duration of new oxygen use|Duration of hospitalization|Duration of mechanical ventilation|Proportion of increased ultrasensitive C-reactive protein (usCRP) (defined as usRCP > 7 mg/L)|Proportion of decrease in erythrocyte sedimentation rate (ESR) (defined as ESR decrease > 50% compared to baseline (Day 0))|Proportion of increase in eosinophils (defined as eosinophils increase > 50% compared to baseline (Day 0))|Proportion of increased d-dimer (defined as d-dimer > 500 mg/dL)|Variation in oxygen saturation compared to baseline (Day 0)|Disease duration|Change in viral load from baseline to Day 5|Proportion of post-COVID mental symptoms|Proportion of post-COVID physical symptoms|Proportion of post-COVID overall symptoms
|
|
NCT04392128
|
Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE) |
Withdrawn |
Phase 2 |
Sep/02/2020 |
Sep/02/2020 |
- Alternative id - 2020-005|2020-002002-45
- Interventions - Drug: Hydroxychloroquine Sulfate 200 MG [Plaquenil]|Drug: Azithromycin 250 MG Oral Capsule|Drug: Placebo oral tablet|Drug: Placebo oral capsule
- Study type - Interventional
- Study results - No Results Available
- Locations - Institut de Cancérologie Strasbourg Europe, Strasbourg, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
- Enrollment - 0
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - Evaluation of the efficacy of hydroxychloroquine and azithromyncine on the viral load drop at day 5.|Clinical evolution|Proportion of patients progressing to a severe form|Mortality|Evaluation of viral load drop|Tolerance of study treatment|Evaluation of the seroconversion|NK immunological study|Hospitalisation duration|Impact of the study treatment on the treatment of the hematological disease|Monitoring of the QT space|Dosage of residual concentration of azithromycine and hydroxychloroquine.|T immunological study
|
|
NCT04394182
|
Ultra Low Doses of Therapy With Radiation Applicated to COVID-19 |
Recruiting |
Not Applicable |
Apr/21/2020 |
Apr/21/2021 |
- Alternative id - 20.4.1597-GHM
- Interventions - Radiation: Ultra-Low-dose radiotherapy|Device: ventilatory support with oxygen therapy|Drug: Lopinavir/ritonavir|Drug: Hydroxychloroquine|Drug: Azithromycin|Drug: Piperacillin/tazobactam|Drug: Low molecular weight heparin|Drug: Corticosteroid injection|Drug: Tocilizumab
- Study type - Interventional
- Study results - No Results Available
- Locations - Hospital La Milagrosa, GenesisCare, Madrid, Spain|Hospital Vithas Valencia Consuelo, Valencia, Spain
- Study designs - Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Supportive Care
- Enrollment - 15
- Age - 18 Years to 120 Years (Adult, Older Adult)
- Outcome measures - Oxygen Therapy Status at Day 2|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 2|Blood Gas Analysis at Day 2|Blood Test at Day 2|Oxygen Therapy Status at Day 5|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 5|Blood Test at Day 5|Oxygen Therapy Status at Day 7|Oxygen Saturation (Sat02; Pulse oximeter measurement) at Day 7|Blood Test at Day 7|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan at Day 7|Recovery time|COVID-19 status|Change from baseline Total Severity Score (TSS) analyzed in a thoracic CT scan al Month 1|Acute Toxicity
|
|
NCT04344379
|
Prevention of SARS-CoV-2 in Hospital Workers s Exposed to the Virus |
Completed |
Phase 3 |
Apr/17/2020 |
Jun/18/2020 |
- Alternative id - APHP200386|2020-001273-73
- Interventions - Drug: hydroxychloroquine|Drug: azithromycin|Drug: hydroxychloroquine placebo
- Study type - Interventional
- Study results - No Results Available
- Locations - Hopial Avicenne, Bobigny, France|Hôpital GHU Paris Saclay, Le Kremlin-Bicêtre, France|Hôpital Saint Antoine, Paris, France|Hôpital Broca, Paris, France|Hôpital La Pitié-Salpétrière, Paris, France|Hôpital Cochin, Paris, France|Hôpital européen Georges Pompidou, Paris, France|Hôpital Necker, Paris, France
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention
- Enrollment - 122
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - To assess the impact of hydroxychloroquine and azithromycin on the prevention of SARS-CoV-2 contamination in hospital workers exposed to 40 days of treatment.|Reducing clinical episodes due to suspected SARS-2 CoV infection confirmed by PCR|Reducing seroconversion for SARS-CoV-2 without any clinical sign|Evaluation of drug tolerance in the study|Evaluation on work stopping of hospital workers|Observance of treatment measured by plasmatic concentrations of hydroxychloroquine or azythromycine|Incidence of cardiologic events
|
|
NCT04334512
|
A Study of Quintuple Therapy to Treat COVID-19 Infection |
Recruiting |
Phase 2 |
Jun/22/2020 |
Sep/01/2024 |
- Alternative id - PRG-044
- Interventions - Drug: Hydroxychloroquine|Drug: Azithromycin|Dietary Supplement: Vitamin C|Dietary Supplement: Vitamin D|Dietary Supplement: Zinc
- Study type - Interventional
- Study results - No Results Available
- Locations - ProgenaBiome, Ventura, California, United States
- Study designs - Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
- Enrollment - 600
- Age - 18 Years and older (Adult, Older Adult)
- Outcome measures - The rate of recovery of mild or moderate COVID-19 in patients using Quintuple Therapy|Reduction or Progression of Symptomatic Days|Assess the safety of Quintuple Therapy|Assess the safety of Quintuple Therapy via pulse|Assess the safety of Quintuple Therapy via oxygen saturation|Assess the safety of Quintuple Therapy via EKG|Assess Tolerability of Quintuple Therapy
|
